CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC

This article was originally published here

“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need,” said Sandra Horning, MD,

The post CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply